PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies today announced the completion of two independent studies on its topical treatment of Onychomycosis, a common fungal nail infection. The studies were conducted with a formulation based on HemCon’s newest proprietary platform technology that provides a controlled release broad spectrum antifungal and antibacterial agent to fight infection.
